Senator Tina Smith (Democratic-Minnesota) recently sold shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in Insulet stock on May 7th.
Senator Tina Smith also recently made the following trade(s):
- Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 5/7/2026.
- Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 4/29/2026.
- Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 4/29/2026.
- Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
- Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.
Insulet Stock Performance
Shares of NASDAQ PODD traded down $1.22 during trading on Friday, reaching $147.46. 1,441,853 shares of the company traded hands, compared to its average volume of 1,643,372. The firm has a 50 day simple moving average of $199.93 and a 200-day simple moving average of $256.98. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $10.21 billion, a PE ratio of 34.29, a P/E/G ratio of 1.21 and a beta of 1.20. Insulet Corporation has a 52-week low of $145.59 and a 52-week high of $354.88.
Insiders Place Their Bets
In other news, Director Michael R. Minogue acquired 2,030 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were acquired at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.36% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on PODD. Barclays dropped their price target on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. Leerink Partners dropped their price target on shares of Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Sanford C. Bernstein dropped their price objective on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Weiss Ratings raised shares of Insulet from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 1st. Finally, The Goldman Sachs Group set a $237.00 price objective on shares of Insulet in a report on Thursday, May 7th. Nineteen research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average target price of $257.09.
View Our Latest Stock Analysis on Insulet
Institutional Investors Weigh In On Insulet
A number of hedge funds have recently bought and sold shares of the business. Quantinno Capital Management LP raised its stake in Insulet by 35.1% during the first quarter. Quantinno Capital Management LP now owns 224,951 shares of the medical instruments supplier’s stock valued at $47,204,000 after purchasing an additional 58,388 shares in the last quarter. Delta Global Management LP purchased a new stake in Insulet during the first quarter valued at $2,156,000. OMERS ADMINISTRATION Corp increased its position in Insulet by 23.9% during the first quarter. OMERS ADMINISTRATION Corp now owns 12,188 shares of the medical instruments supplier’s stock valued at $2,558,000 after acquiring an additional 2,348 shares during the last quarter. Entropy Technologies LP bought a new position in Insulet during the first quarter valued at $6,277,000. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in Insulet by 59.0% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 4,420 shares of the medical instruments supplier’s stock valued at $927,000 after acquiring an additional 1,640 shares during the last quarter.
About Senator Smith
Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.
About Insulet
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Featured Articles
- Five stocks we like better than Insulet
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
-SHOGGOTH.png){kind=small}